[{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"JK07","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Salubris Biotherapeutics \/ Shenzhen Salubris Pharmaceuticals Co.Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Salubris Biotherapeutics \/ Shenzhen Salubris Pharmaceuticals Co.Ltd."},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"JK07","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JK06","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Salubris Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Salubris Biotherapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Salubris Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : JK06 is a first-in-class quadrivalent, biparatopic antibody drug conjugate (ADC) that selectively targets 5T4 with an MMAE payload. It is being investigated for solid tumoors.

                          Brand Name : JK06

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 05, 2024

                          Lead Product(s) : JK06

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : JK07 is a recombinant fusion protein consisting of a fully human immunoglobulin IgG1 monoclonal antibody, which is being evaluating in the mid-stage clinical trials for patients with HFrEF and HFpEF.

                          Brand Name : JK07

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : JK07

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $35.0 million

                          Deal Type : Financing

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.

                          Brand Name : JK07

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 28, 2023

                          Lead Product(s) : JK07

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS

                          Deal Size : $35.0 million

                          Deal Type : Financing

                          blank